Skip to main content

Vertigo

3
Pipeline Programs
5
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

JSC Valenta Pharmaceuticals
2 programs
1
1
VespireitPhase 41 trial
BuspironePhase 31 trial
Active Trials
NCT05430217Completed268Est. May 2022
NCT06321341Recruiting160Est. Dec 2026
Apsen Farmaceutica
Apsen FarmaceuticaBrazil - São Paulo
1 program
1
APSLXRPhase 11 trial
Active Trials
NCT04674735Withdrawn0Est. Jun 2025
Otolith Labs
Otolith LabsDC - Washington
3 programs
OtobandN/A1 trial
Otoband ExperimentalN/A1 trial
Transcranial vibrating systemN/A1 trial
Active Trials
NCT04869020Completed40Est. Nov 2022
NCT05960786Completed109Est. Dec 2023
NCT03795168Terminated1Est. Apr 2019
Eisai
EisaiChina - Liaoning
1 program
MerislonPHASE_41 trial
Active Trials
NCT00474409Withdrawn0

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
JSC Valenta PharmaceuticalsVespireit
EisaiMerislon
JSC Valenta PharmaceuticalsBuspirone
Apsen FarmaceuticaAPSLXR
Otolith LabsOtoband Experimental
Otolith LabsOtoband
Otolith LabsTranscranial vibrating system

Clinical Trials (7)

Total enrollment: 578 patients across 7 trials

NCT06321341JSC Valenta PharmaceuticalsVespireit

Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

Start: Jan 2024Est. completion: Dec 2026160 patients
Phase 4Recruiting
NCT00474409EisaiMerislon

A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

Start: May 20070
Phase 4Withdrawn
NCT05430217JSC Valenta PharmaceuticalsBuspirone

Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

Start: Jan 2022Est. completion: May 2022268 patients
Phase 3Completed
NCT04674735Apsen FarmaceuticaAPSLXR

Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease

Start: Jan 2023Est. completion: Jun 20250
Phase 1Withdrawn
NCT05960786Otolith LabsOtoband Experimental

Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand

Start: Feb 2023Est. completion: Dec 2023109 patients
N/ACompleted
NCT04869020Otolith LabsOtoband

Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting

Start: Apr 2021Est. completion: Nov 202240 patients
N/ACompleted
NCT03795168Otolith LabsTranscranial vibrating system

Transcranial Vibrating System for Improving Vestibular Physical Therapy

Start: Jan 2019Est. completion: Apr 20191 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 578 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.